Spore-ing change: Rua Bioscience psilocybin study targets meth addiction

Spore-ing change: Rua Bioscience psilocybin study targets meth addiction
Gisborne-based pharmaceutical company Rua Bioscience is hoping mushrooms can help cure meth addiction. (Image: Supplied)
Gregor Thompson
Rua Bioscience is exploring psilocybin-containing mushrooms’ potential in treating methamphetamine addiction.The clinical study, dubbed Tū Wairua (standing with strength and spiritual connectedness), intends to combine historic Māori practices with modern science to tackle meth addiction.The New Zealand Exchange-listed (NZX) and the Gisborne-based medical cannabis company announced Phase I of the new trial on Tuesday.“Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessio...

More Markets

Softer market ignores Budget
Markets Market Close

Softer market ignores Budget

Post-Budget, all eyes are on the Reserve Bank's OCR announcement next Wednesday.

Jamie Gray 23 May 2025
Restaurant Brands ‘does not seem to care’: Shareholder
Retail

Restaurant Brands ‘does not seem to care’: Shareholder

At the fiery annual meeting, a shareholder called the Californian market a ‘sinkhole’.

Gregor Thompson 23 May 2025
Channel increases dividend, mulls ASX listing
Infrastructure

Channel increases dividend, mulls ASX listing

Dividend up from 11c to between 12c and 12.5c. 

Ian Llewellyn 23 May 2025
Oceania CEO hopes sales cadence eases investor concerns
Property

Oceania CEO hopes sales cadence eases investor concerns

Suzanne Dvorak is "very positive" sales momentum will continue. 

Gregor Thompson 23 May 2025